Abstracts Archive - Page 1298 of 2425 - ACR Meeting Abstracts

Abstract Number: 1387 • 2017 ACR/ARHP Annual Meeting
In-Depth Temperature of Small and Large Joints Assessed By Microwave Radiometry As an Additional Biomarker in Rheumatoid Arthritis
Katerina Laskari¹, George Pentazos¹, George Konstantonis¹, Ioannis Raftakis², Elias Siores³ and Petros P Sfikakis¹, ¹Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece, ²Rheumatology Department, Asklepion General Hospital, Athens, Greece, ³Institute of Materials Research and Innovation, University of Bolton, Bolton, United Kingdom
Background/Purpose: Microwave Radiometry (MR) is an easy-to-perform, rapid, non-invasive, objective method, able to measure in-depth tissue temperature. In a proof-of-concept study using joint ultrasound as…
Abstract Number: 1388 • 2017 ACR/ARHP Annual Meeting
Fatigue Is Strongly Associated with the Patient Global Assessment and May Affect Disease Severity and Clinical Remission in Patients with Rheumatoid Arthritis: A Cross-Sectional Study from IORRA, a Large Observational Cohort of Japanese Rheumatoid Arthritis Patients
Naoki Sugimoto¹, Eiichi Tanaka¹, Eisuke Inoue^1,2, Kumiko Saka¹, Eri Sugano¹, Naohiro Sugitani¹, Moeko Ochiai¹, Yoko Shimizu¹, Rei Yamaguchi¹, Katsunori Ikari¹, Ayako Nakajima¹, Atsuo Taniguchi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Fatigue is a common complaint in patients with rheumatoid arthritis (RA)1. However, its impact on disease activity and clinical remission in patients with RA…
Abstract Number: 1389 • 2017 ACR/ARHP Annual Meeting
Serum Progranulin Antibodies (PGRN-abs) in Rheumatoid Arthritis Patients Being Negative for RF-IgM and ACCP-IgG
Gunter Assmann¹, Silke Zinke², Moritz Gerling³, Natalie Fadle³, Klaus Dieter Preuss³, Michael Pfreundschuh³ and Lorenz Thurner³, ¹Medicine I, University Medical School of Saarland, 66424, Germany, ²Rheumapraxis, Rheumatology Center Berlin - Lichtenberg, Berlin, Germany, ³Medicine I, Jose Carreras Center, University of Saarland, Homburg, Germany
Background/Purpose: Until recently, most research on progranulin (PGRN) had been focused on its role in neurogenerative diseases as frontotemporal dementia. After the detection of elevated…
Abstract Number: 1390 • 2017 ACR/ARHP Annual Meeting
Agreement between the DAS28-ESR and the DAS28-CRP and Factors Related to the Discrepancies between Disease Activity Levels According to These 2 Scores in Patients with Early Rheumatoid Arthritis
Cécile Gaujoux-Viala¹, Mohamed Belkacemi², Alain Cantagrel³, Bruno Fautrel⁴ and Bernard Combe⁵, ¹Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ²EA2415 Montpellier University, Montpellier, France, ³Rheumatology, Toulouse University Hospital and Toulouse University, Toulouse, France, ⁴UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ⁵Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France
Background/Purpose: DAS28 is often used as a treatment decision tool in patients with rheumatoid arthritis (RA) in the daily clinic. Although different versions of DAS28…
Abstract Number: 1391 • 2017 ACR/ARHP Annual Meeting
Ultrasound Response to Tocilizumab in Surgically Replaced Joints and Surgically Operated Joint Areas of Rheumatoid Arthritis Patients
Evan Choate¹, Gurjit S. Kaeley², Jenny Brook³, John Fitzgerald⁴, David Elashoff⁵ and Veena K. Ranganath⁶, ¹David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, ³Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁴David Geffen School of Medicine, Division of Rheumatology, Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, ⁵David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, ⁶Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Rheumatoid Arthritis (RA) disease activity outcomes are used for treatment decisions (ie. DAS28-ESR). Surgically operated joints (SOJ) are assumed not to respond to therapy…
Abstract Number: 1392 • 2017 ACR/ARHP Annual Meeting
Effect Size Comparison of Ultrasound Measures in Rheumatoid Arthritis
Veena K. Ranganath¹, David Elashoff², Jenny Brook³, Ami Ben-Artzi⁴, Geraldine Navarro⁵, Lynnette Avedikian-Tatosyan⁶, George Karpouzas⁷, William Martin⁵, Tanaz A. Kermani⁵, Soo Choi⁵ and Gurjit S. Kaeley⁸, ¹Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, ³Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁴Medicine, Cedars, Beverly Hills, CA, ⁵Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁶Healthcare Partners, Los Angeles, CA, ⁷Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁸Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL
Background/Purpose: Currently there are several outcome metrics used for the assessment and quantification of musculoskeletal (MSK) ultrasound inflammatory burden in rheumatoid arthritis (RA). This study…
Abstract Number: 1393 • 2017 ACR/ARHP Annual Meeting
Patient Characteristics, Treatment Strategy or Investigator Effect: An Analysis of Factors Driving Variation in Outcomes in Early Rheumatoid Arthritis
Cheryl Barnabe¹, Orit Schieir², Glen Hazlewood¹, Susan J. Bartlett³, Carol A Hitchon⁴, Janet E. Pope⁵, Gilles Boire⁶, Edward C. Keystone⁷, Diane Tin⁸, B Haraoui⁹, Vivian P. Bykerk¹⁰ and Carter Thorne¹¹, ¹Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁶Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ¹⁰2-005, Mt Sinai Hospital, Toronto, ON, Canada, ¹¹University of Toronto, Newmarket, ON, Canada
Background/Purpose: Outcomes in ERA are largely thought to reflect individual prognostic factors and treatment strategy employed. We hypothesize that an additional factor may be the…
Abstract Number: 1394 • 2017 ACR/ARHP Annual Meeting
Comparison of Improvements in Disease Activity between Classes of Biologic Disease Modifying Anti-Rheumatic Drugs in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort
Richard Gliklich¹, Zhaohui Su², Gregory Donadio¹, Tom Brecht², Costas Boussios², Francis O’Donovan³, Charles Kekeh³, Anna Lafontant², Kathryn Starzyk² and Vandana Menon², ¹OM1, Inc, Cambridge, MA, ²Research, OM1, Inc, Cambridge, MA, ³Data Science, OM1, Inc, Cambridge, MA
Background/Purpose: RA is estimated to affect approximately 1.3 million adults in the US and accounts for a significant proportion of US health care spend with…
Abstract Number: 1395 • 2017 ACR/ARHP Annual Meeting
Patient Reported Outcomes in Rheumatoid Arthritis: Best Domain, Best Interface
Iris Navarro-Millán¹, Anna Cornelius-Schecter¹, Aprajita Jagpal², Bernadette Johnson³, Liana Fraenkel⁴, Monika M. Safford¹ and Jeffrey R. Curtis², ¹Weill Cornell Medical College, New York, NY, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT
Background/Purpose: Quantifiable measures of patients’ symptoms such as patient reported outcomes (PROs) provides the physician with quantifiable information of subjective symptoms experienced by patients with…
Abstract Number: 1396 • 2017 ACR/ARHP Annual Meeting
Can 3 0-10 Physician Visual Analog Scales (VAS) to Assess Levels of Inflammation, Damage and Distress Offer Comprehensive Quantitative Data That May be As Informative As Detailed, Formal Swollen and Tender Joint Counts?
MJ Bergman¹ and Theodore Pincus², ¹Drexel University College of Medicine, Philadelphia, PA, ²Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Management of patients with rheumatoid arthritis (RA) remains primarily according to a patient history and physical examination, unlike in many other chronic diseases, in…
Abstract Number: 1397 • 2017 ACR/ARHP Annual Meeting
American College of Rheumatology Response Rates Determined Using 28 Versus 68/66 Joint Count in Patients with Rheumatoid Arthritis Receiving Tofacitinib in Phase 3 Studies
Josef S. Smolen¹, William Shergy², Grace C. Wright³, Ryan DeMasi⁴, Kenneth Kwok⁵, Christopher F Mojcik⁵, Noriko Iikuni⁵, Svitlana Tatulych⁶ and Gustavo Citera⁷, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Rheumatology Associates of North Alabama, Huntsville, AL, ³NYU Langone Medical Center, New York, NY, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Groton, CT, ⁷Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In a clinical trial setting, standard criteria for measuring the…
Abstract Number: 1398 • 2017 ACR/ARHP Annual Meeting
Sleep and Physical Activity: An Objective Profile of People with Rheumatoid Arthritis
Sean McKenna¹, Marie Tierney², Sandy Fraser³, Aoife O'Neill⁴ and Norelee Kennedy¹, ¹Department of Clinical Therapies, University of Limerick, Ireland, Limerick, Ireland, ²Discipline of General Practice, National University of Galway, Ireland, Galway, Ireland, ³Department of Rheumatology, University Hospitals Limerick, Ireland, Limerick, Ireland, ⁴Department of Mathematics, University of Limerick, Ireland, Limerick, Ireland
Background/Purpose: Regular physical activity is important for people with rheumatoid arthritis (RA). Sleep requirements for adults should be on a ‘sleep needs spectrum’ of between…
Abstract Number: 1399 • 2017 ACR/ARHP Annual Meeting
Tissues Are Differently Modulated By Tocilizumab and Methotrexate; Assessment of Connective Tissue Metabolites in the Ambition Study
Anne C. Bay-Jensen¹, Anne Sofie Siebuhr¹, Christian S. Thudium² and Morten Asser Karsdal¹, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
Background/Purpose: The response to any treatment in rheumatoid arthritis (RA) is assessed by symptomatic changes, such as swollen joint count and DAS28. However, such assessments…
Abstract Number: 1400 • 2017 ACR/ARHP Annual Meeting
Beneficial Effect of Anti-IL-6 Blockade on Insulin Resistance and Insulin Sensitivity in Patients with Rheumatoid Arthritis
Raquel López-Mejías¹, Fernanda Genre¹, Sara Remuzgo-Martínez¹, Begoña Ubilla¹, Veronica Mijares¹, Jaime Calvo-Alen², Javier Llorca³, Santos Castañeda⁴ and Miguel Angel González-Gay⁵, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Rheumatology Department, Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ³Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁴Hospital Universitario La Princesa. IIS-IP. Madrid. Spain, Madrid, Spain, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL. School of Medicine, University of Cantabria., Santander, Spain
Background/Purpose: Systemic inflammation, insulin resistance, and endothelial dysfunction were implicated in the development of cardiovascular disease in rheumatoid arthritis (RA) [1-3]. Since insulin resistance can…
Abstract Number: 1401 • 2017 ACR/ARHP Annual Meeting
Persistence of Mast Cell-Rich Synovitis Is Associated with Lack of Response to Synthetic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
Felice Rivellese, Frances Humby, Sara Pagani, Alessandra Nerviani and Costantino Pitzalis, Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
Background/Purpose: Mast cells (MCs) are immune cells infiltrating the synovial membrane and implicated in the pathogenesis of Rheumatoid Arthritis, but their strict contribution to disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].